<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3079">
  <stage>Registered</stage>
  <submitdate>10/02/2011</submitdate>
  <approvaldate>10/02/2011</approvaldate>
  <nctid>NCT01297322</nctid>
  <trial_identification>
    <studytitle>RESPECT Trial - (Rapid Extravascular Sealing Via PercutanEous Collagen ImplanT)</studytitle>
    <scientifictitle>A Multi-Center, Prospective, Randomized, Controlled, Trial to Evaluate the Safety and Efficacy of the Cardiva VASCADE Vascular Closure System (VCS) vs. Manual Compression for the Management of the Femoral Arteriotomy After Percutaneous Endovascular Procedures</scientifictitle>
    <utrn />
    <trialacronym>RESPECT</trialacronym>
    <secondaryid>PTL 0243</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Surgical Wound</healthcondition>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Manual compression
Treatment: devices - Cardiva VASCADE Vascular Closure System

Active Comparator: Manual compression - 

Experimental: VASCADE Vascular Closure System - 


Other interventions: Manual compression
Standard of Care

Treatment: devices: Cardiva VASCADE Vascular Closure System
Investigational Hemostatic Vascular Closure System

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to Hemostasis (TTH) - Primary effectiveness endpoint - elapsed time between device (VASCADE) or sheath (manual compression) removal and first observed and confirmed arterial hemostasis.</outcome>
      <timepoint>Up to 1 hour</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Rate of Combined Access Site-related Major Complications - Primary safety endpoint
Access site-related bleeding requiring transfusion;
Vascular injury requiring repair (via surgery, ultrasound guided compression, transcatheter embolization or stent graft);
New ipsilateral lower extremity ischemia causing a threat to the viability of the limb and requiring surgical or additional percutaneous intervention. This compromised blood flow is documented by subject symptoms, physical exam and/or a decreased or absent blood flow on lower extremity angiogram.;
Access site-related infection requiring intravenous antibiotics and/or extended hospitalization;
New onset access site-related neuropathy in the ipsilateral lower extremity requiring surgical repair;
Permanent access site-related nerve injury. (&gt; 30 days)</outcome>
      <timepoint>30 days +/- 7 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Ambulation (TTA) - Secondary effectiveness endpoint - elapsed time between device (VASCADE) or sheath (manual compression) removal and when subject stands and walks 20 feet without evidence of arterial re-bleeding</outcome>
      <timepoint>Up to 1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Discharge Eligibility (TTDE) - Secondary effectiveness endpoint - elapsed time between device (VASCADE) or sheath (manual compression) removal and when subject is medically able to be discharged based solely on the assessment of the access site, as determined by the medical team</outcome>
      <timepoint>Up to 2 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Hospital Discharge (TTHD) - Secondary effectiveness endpoint - elapsed time between device (VASCADE) or sheath (manual compression) removal and when subject is actually discharged from the hospital</outcome>
      <timepoint>Up to 2 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Device Success - Secondary effectiveness endpoint - ability to deploy the delivery system, deliver the collagen, and achieve hemostasis with VASCADE alone or with adjunctive compression</outcome>
      <timepoint>Up to 1 day</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Procedure Success - Secondary effectiveness endpoint - attainment of final hemostasis using any method and freedom from major vascular complications through 30 days</outcome>
      <timepoint>30 days +/- 7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of Combined Minor Access Site Complications - Secondary safety endpoint
Access site-related bleeding requiring greater than 30 minutes to achieve hemostasis;
Access site-related hematoma &gt; 6 cm;
Late access site-related bleeding (following hospital discharge);
Ipsilateral lower extremity arterial emboli;
Ipsilateral deep vein thrombosis;
Access site-related vessel laceration;
Access site wound dehiscence;
Localized access site infection treated with intramuscular or oral antibiotics;
Arteriovenous fistula not requiring treatment;
Pseudoaneurysm requiring thrombin injection or fibrin adhesive injection;
Pseudoaneurysm not requiring treatment;
New onset access site-related neuropathy in the ipsilateral lower extremity not requiring surgical repair;
Ipsilateral pedal pulse diminished by two grades or transiently lost.</outcome>
      <timepoint>30 days +/- 7 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Pre-Operative 

          -  Patients undergoing an elective, non-emergent diagnostic or interventional
             endovascular procedure via the common femoral artery using a 6 or 7 Fr introducer
             sheath

        Pre-Operative</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Advanced refusal of blood transfusion, if necessary;

          2. Active systemic or a cutaneous infection or inflammation;

          3. Pre-existing immunodeficiency disorder and/or chronic use of systemic steroids;

          4. Known, significant history of bleeding diathesis, coagulopathy, von Willebrand's
             disease or current platelet count &lt; 100,000 cells/mm3, baseline INR =1.8, or
             fibrinogen level less than 150 mg/dl (if received a fibrinolytic agent within prior 24
             hours);

          5. Severe co-existing morbidities having a life expectancy of less than 30 days;

          6. Currently involved in any other investigational clinical trial;

          7. Ipsilateral femoral arteriotomy within the previous 30 days;

          8. Planned endovascular procedure within the next 30 days;

          9. Previous ipsilateral femoral artery closure using a permanent implant-based closure
             device;

         10. Previous vascular grafts or surgery at the target vessel access site;

         11. History of symptomatic peripheral arterial disease, revascularization or deep vein
             thrombosis in the ipsilateral limb;

         12. Unilateral or bilateral lower extremity amputation(s);

         13. Significant anemia with a hemoglobin level less than 10 g/dL or a hematocrit less than
             30%;

         14. Renal insufficiency (serum creatinine of &gt; 2.5 mg/dl);

         15. Females who are pregnant, planning to become pregnant within 3 months of the
             procedure, or lactating;

         16. Extreme morbid obesity (BMI greater than 45 kg/m2) or underweight (BMI less than 20
             kg/m2);

         17. Unable to routinely walk at least 20 feet without assistance (see protocol);

         18. Known allergy/adverse reaction to bovine derivatives, sodium hyaluronate or hyaluronan
             preparations;

         19. Procedures that extend hospitalization (e.g., staged endovascular procedure, CABG);

         20. Administration of low molecular weight heparin (LMWH) within 8 hours of the procedure.

        Intra-op Exclusion Criteria

          1. An introducer sheath with an overall length greater than 11 cm, or not 6 Fr or 7 Fr
             diameter;

          2. Femoral artery diameter less than 6 mm at access site;

          3. Difficult insertion of procedural sheath or needle stick problems at the onset of the
             procedure (e.g., multiple stick attempts, "back wall stick", etc.);

          4. Angiographic evidence of more than minimal calcium, atherosclerotic disease, or stent
             within 1 cm of the puncture site;

          5. Overlapping Common Femoral Vein and Femoral Artery at access site;

          6. Placement of ipsilateral venous sheath during procedure;

          7. Arterial access site located not at common femoral artery (e.g., on or below the
             bifurcation, above the lower border of the inferior epigastric artery, or above the
             pelvic brim);

          8. More than one access site required;

          9. Loss of distal pulses in the ipsilateral extremity during the procedure;

         10. Subjects receiving unfractionated heparin with an ACT greater than 300 seconds in the
             absence of a glycoprotein IIb/IIIa inhibitor or greater than 250 seconds in the
             presence of a glycoprotein IIb/IIIa inhibitor (may wait to remove introducer sheath
             until ACT level reaches the target value);

         11. Intra-procedural bleeding around sheath, or suspected intraluminal thrombus, hematoma,
             pseudoaneurysm, or AV fistula;

         12. Systemic hypertension (BP greater than 180/110 mmHg) or hypotension (BP less than
             90/60 mmHg) prior to randomization;

         13. Length of the tissue tract, the distance between the anterior arterial wall and skin,
             is estimated to be less than 2.5 cm;

         14. If the physician deems that a different method should be used to achieve hemostasis of
             the arterial site or that the subject should not attempt ambulation according to the
             protocol requirements.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>420</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>St. Vincent's Hospital Melbourne - Melbourne</hospital>
    <postcode>3065 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Delaware</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>West Virginia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Cardiva Medical, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objective of this trial is to demonstrate the safety and effectiveness of the Cardiva
      VASCADE Vascular Closure System (VCS) in sealing femoral arterial access sites. Hypothesis:
      The Cardiva VASCADE VCS provides times to hemostasis (TTH) and time to ambulation (TTA)
      results that are less than manual compression by a clinically meaningful and statistically
      significant margin. The rate of major access site-related complications with the Cardiva
      VASCADE VCS is non-inferior to the major complication rates of manual compression for
      sealing femoral arterial access sites.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01297322</trialwebsite>
    <publication>Lehmann KG, Heath-Lange SJ, Ferris ST. Randomized comparison of hemostasis techniques after invasive cardiovascular procedures. Am Heart J. 1999 Dec;138(6 Pt 1):1118-25.
Simon A, Bumgarner B, Clark K, Israel S. Manual versus mechanical compression for femoral artery hemostasis after cardiac catheterization. Am J Crit Care. 1998 Jul;7(4):308-13.
Kussmaul WG 3rd, Buchbinder M, Whitlow PL, Aker UT, Heuser RR, King SB, Kent KM, Leon MB, Kolansky DM, Sandza JG Jr. Rapid arterial hemostasis and decreased access site complications after cardiac catheterization and angioplasty: results of a randomized trial of a novel hemostatic device. J Am Coll Cardiol. 1995 Jun;25(7):1685-92.
Casta√±eda F, Swischuk JL, Smouse HB, Brady T. Gelatin sponge closure device versus manual compression after peripheral arterial catheterization procedures. J Vasc Interv Radiol. 2003 Dec;14(12):1517-23.
Hoffer EK, Bloch RD. Percutaneous arterial closure devices. J Vasc Interv Radiol. 2003 Jul;14(7):865-85. Review.
Gerckens U, Cattelaens N, Lampe EG, Grube E. Management of arterial puncture site after catheterization procedures: evaluating a suture-mediated closure device. Am J Cardiol. 1999 Jun 15;83(12):1658-63.
Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, Pinnow EE, Kent KM, Pichard AD, Satler LF, Weissman NJ, Lindsay J, Fuchs S. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003 Oct 15;92(8):930-5.
Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998 Apr 30;17(8):873-90. Erratum in: Stat Med 1999 May 30;18(10):1293.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>James B. Hermiller, Jr., MD, FACC, FSCAI</name>
      <address>The St. Vincent Heart Center of Indiana, St. Vincent Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>